Browse studies

Find your next paid study

15 recruiting studies matching your filters

A Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez

In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at grea…

Epidermolysis Bullosa, DystrophicEpidermolysis Bullosa, Junctional

Estimated

~$10 – $1,125

Chiesi Farmaceutici S.p.A.NCT06423573

Phase 3

A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa

The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 y…

Epidermolysis Bullosa (EB)

Estimated

~$10 – $8,750

Paradigm TherapeuticsNCT07482787

Observational

Impact of Body Positioning on EndoFLIP Measurements: A Comparative Study of Supine and Left Lateral Decubitus Positions

This is a prospective, single-center, crossover study comparing EndoFLIP measurements obtained in two patient positions, supine and left lateral decubitus, in …

DysphagiaEsophageal StrictureEpidermolysis Bullosa (EB)+3 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07780981

Phase 2

A Phase II, Closed Label, Placebo Controlled, Randomized, Double-Blinded Clinical Trial to Evaluate the Efficacy and Safety of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex (TAMES)

This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (2 years of age and old…

Epidermolysis Bullosa Simplex

Estimated

~$10 – $8,750

BioMendics, LLCNCT07027345

Phase 2

A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa

This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel i…

Epidermolysis Bullosa (EB)Dystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa

Estimated

~$10 – $7,500

Xinnate ABNCT06594393

Phase 2

A Pilot Trial to Evaluate the Efficacy and Safety of Filsuvez in the Treatment of Moderate-to-Severe Epidermolysis Bullosa Simplex

This pilot study will look at whether the topical Birch Triterpenes (Filsuvez) gel is safe and helpful for adults and children 6 months of age and older who ha…

Epidermolysis Bullosa Simplex

Estimated

~$10 – $6,250

Stanford UniversityNCT07756138

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

The goal of this observational study is to evaluate the long-term safety and wound healing durability (up to 15 years) for participants with Recessive Dystroph…

Recessive Dystrophic Epidermolysis Bullosa

Estimated

~$10 – $1,050

Abeona Therapeutics, IncNCT07700966

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large,…

Epidermolysis Bullosa Dystrophica

Estimated

~$10 – $750

Stanford UniversityNCT01019148

Phase 1

Mesenchymal Stem Cell Extracellular Vesicles for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Wounds

INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND …

Dystrophic Epidermolysis Bullosa

Estimated

~$10 – $8,750

Aegle TherapeuticsNCT04173650

Phase 1

A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment

Herlitz junctional epidermolysis bullosa (H-JEB), an incurable, fatal, inherited skin disease, is caused by loss-of-function mutations in the LAMA3, LAMB3 or L…

Junctional Epidermolysis Bullosa

Estimated

~$10 – $6,250

University of Southern CaliforniaNCT03526159

Phase 1

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves woun…

Epidermolysis BullosaEpidermolysis Bullosa AcquisitaDystrophic Epidermolysis Bullosa+1 more

Estimated

~$10 – $7,500

M. Peter MarinkovichNCT06834035

A Prospective, Observational, Long-Term Follow-Up (LTFU) Study to Evaluate the Long-Term Safety of the Krystal Biotech, Inc. Gene Therapy Backbone Products Using HSV-1 Backbone

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy product…

Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa

Estimated

~$10 – $1,050

Krystal Biotech, Inc.NCT04917887